Coherus BioSciences (CHRS) Stock Highlights

1 | -3.85%

2024-09-25 05:30:46

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Statistics

Range Today

1 1.05

Volume Today 1.77M

Range 1 Year

0.97 4.36

Volume 1 Year 870.34M

Range 3 Year

0.97 19.32

Volume 3 Year 1.6B

Range 10 Year

0.97 38.1

Volume 10 Year 2.83B

Highlights

Market Capitalization 117.51M (small)

Floating Shares 103.3M

Current Price 1

Price To Earnings -2.92

Price To Revenue 0.78

Earnings Per Share -0.38

Payout Ratio 0%

Performance

Latest -3.85%

1 Month -29.08%

3 Months -40.83%

6 Months -57.08%

1 Year -77.06%

3 Years -94.27%

5 Years -95.35%

10 Years -92.16%

Benchmarks

Market Capitalization

204 / 368

Gross Profits

206 / 278

Total Revenue

59 / 300

Total Rank

90 / 368

Free Cashflow

315 / 352

Performance 5 years

329 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.